Vaxcyte's (PCVX) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Vaxcyte (NASDAQ:PCVX - Free Report) in a research note published on Wednesday, Benzinga reports.

Several other brokerages have also recently weighed in on PCVX. BTIG Research raised their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Mizuho lifted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Bank of America increased their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. Jefferies Financial Group lifted their target price on Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reissued a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $147.50.

Vaxcyte Price Performance

Shares of Vaxcyte stock traded down $3.49 on Wednesday, hitting $104.07. The company had a trading volume of 2,681,383 shares, compared to its average volume of 837,683. Vaxcyte has a twelve month low of $46.16 and a twelve month high of $121.06. The stock has a 50-day moving average of $110.06 and a 200-day moving average of $86.69. The firm has a market capitalization of $11.62 billion, a P/E ratio of -22.62 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the company posted ($0.91) earnings per share. Equities analysts predict that Vaxcyte will post -4.33 EPS for the current year.

Insider Buying and Selling

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares of the company's stock, valued at $10,479,005.02. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the transaction, the chief executive officer now directly owns 478,888 shares of the company's stock, valued at $37,822,574.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the transaction, the chief financial officer now owns 90,383 shares in the company, valued at $10,479,005.02. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 115,098 shares of company stock valued at $12,394,473. 3.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Vaxcyte

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company's stock valued at $665,152,000 after purchasing an additional 1,284,883 shares during the period. RA Capital Management L.P. boosted its stake in shares of Vaxcyte by 4.0% in the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company's stock valued at $560,398,000 after buying an additional 312,500 shares during the period. Janus Henderson Group PLC grew its position in Vaxcyte by 9.9% during the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company's stock worth $524,117,000 after buying an additional 692,492 shares in the last quarter. Capital Research Global Investors increased its stake in Vaxcyte by 20.4% during the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company's stock worth $282,839,000 after acquiring an additional 700,414 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company's stock valued at $216,966,000 after acquiring an additional 498,359 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.